… Science was close to accepting [the ad], emails shared with me by Bronner show—an ad sales manager for the American Association for the Advancement of Science, which published the magazine, emailed on September 15 that she would send over paper work “in a bit,” adding that “[a]fter you sign it, I can take your credit card info by phone and submit to accounting.” The price: $9,911.00. But hours later, she wrote back, squashing the deal:
Sorry to say there has [been] a reversal opinion. This has gone up the ladder quite far and our CEO along with the board have come back saying that we cannot accept the ad. We’re concerned about backlash from our members and potentially getting into a battle with the GMO industry.
Something quite similar happened at Nature, a UK-based publication with ad sales operations in the United States. On September 16, an ad sales rep told the Bronner team via email that “I will have an IO [insert order—the contract for an advertisement] for you once I get the thumbs up from Editorial (usually takes them a day or two).” Once that’s signed, he added, “I can call and get your credit card information over the phone, [and] then we are all good.”
But a few days later, instead of closing the deal, the rep asked if Bronner would consider placing the ad in a smaller, related journal called Nature Biotechnology. Bronner declined, and asked again to place it in Nature. The ad rep replied, “We have to do a detailed process for all ad approvals, especially if the ad is not within specs (our terms and conditions). We have passed on the ad for Nature, that’s why the emails about seeking out other options [i.e., Nature Biotechnology] for you.” End of discussion—the sales rep offered no explanation, and soon stopped returning calls or emails. Nor did he return my email and call seeking comment.
As for Science, I talked to Laurie Faraday, the journal’s East regional ad-sales manager, who worked with Bronner’s team on the failed ad deal. She explained that the editorial side weighs in on decisions over advertorial-style ads. Science‘s management found it “a little bit controversial,” and worried that “if we allowed that kind of a piece to be printed in Science, then maybe we’d be subject to the GMO world coming after us.” She added: “Ironically, it’s not that anyone in the organization disagreed with what it [the ad] said. It’s just that we had to consider that the opposite side of the coin might want to start a war in our magazine.” …
It’s not just the GMO lobby, it’s the medical lobby, the pharmaceutical lobby … pretty much any sufficiently wealthy interest group has veto power over virtually all the mainstream scientific journals. These are some of the same journals that jumped on the bandwagon to ridicule Pons and Fleischman for their discovery of “cold fusion”, which is now panning out to be a real phenomenon for which they will probably get a nobel prize at some point. Even Science News has fallen by the wayside after many years of fairly objective reporting. What’s an inquisitive person to do?